# Effect of Different Doses of SAR110894 on Cognition in Patients With Mild to Moderate Alzheimer's Disease on Donepezil

> **NCT01266525** · PHASE2 · COMPLETED · sponsor: **Sanofi** · enrollment: 291 (actual)

## Conditions studied

- Dementia Alzheimer's Type

## Interventions

- **DRUG:** SAR110894
- **DRUG:** placebo (for SAR110894)
- **DRUG:** Donepezil

## Key facts

- **NCT ID:** NCT01266525
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-02
- **Primary completion:** 2013-01
- **Final completion:** 2013-01
- **Target enrollment:** 291 (ACTUAL)
- **Last updated:** 2016-03-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01266525

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01266525, "Effect of Different Doses of SAR110894 on Cognition in Patients With Mild to Moderate Alzheimer's Disease on Donepezil". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01266525. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*